• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cancers, Vol. 14, Pages 3162: Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo
In this study, siRNA was designed for the targeted knockdown of 15-bp deletion-type BRAF mRNA. This siRNA repressed the phosphorylation of extracellular-signal-regulated kinase proteins downstream of BRAF and suppressed cell growth in vitro and in vivo. Furthermore, siRNAs with 2′-O-methyl modifications at positions 2–5 reduce the seed-dependent off-target effects, as confirmed by reporter and microarray analyses. Thus, such siRNA is a promising candidate therapy for 15-bp deletion-type BRAF-induced tumorigenesis.
Source: Cancers - June 28, 2022 Category: Cancer & Oncology Authors: Jiaxuan Song Yoshiaki Kobayashi Yoshimasa Asano Atsushi Sato Hiroaki Taniguchi Kumiko Ui-Tei Tags: Article Source Type: research

Cancers, Vol. 10, Pages 80: Aptamer Therapeutics in Cancer: Current and Future
mi Tanaka Aptamer-related technologies represent a revolutionary advancement in the capacity to rapidly develop new classes of targeting ligands. Structurally distinct RNA and DNA oligonucleotides, aptamers mimic small, protein-binding molecules and exhibit high binding affinity and selectivity. Although their molecular weight is relatively small—approximately one-tenth that of monoclonal antibodies—their complex tertiary folded structures create sufficient recognition surface area for tight interaction with target molecules. Additionally, unlike antibodies, aptamers can be readily chemically synthesized and modifi...
Source: Cancers - March 19, 2018 Category: Cancer & Oncology Authors: Yoshihiro Morita Macall Leslie Hiroyasu Kameyama David Volk Takemi Tanaka Tags: Review Source Type: research